693 related articles for article (PubMed ID: 19710033)
1. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment.
Wong F; Raina N; Richardson R
Gut; 2010 Mar; 59(3):381-6. PubMed ID: 19710033
[TBL] [Abstract][Full Text] [Related]
2. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
Wong F; Pantea L; Sniderman K
Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
[TBL] [Abstract][Full Text] [Related]
3. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
Angeli P; Volpin R; Piovan D; Bortoluzzi A; Craighero R; Bottaro S; Finucci GF; Casiglia E; Sticca A; De Toni R; Pavan L; Gatta A
Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229
[TBL] [Abstract][Full Text] [Related]
4. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.
Angeli P; Volpin R; Gerunda G; Craighero R; Roner P; Merenda R; Amodio P; Sticca A; Caregaro L; Maffei-Faccioli A; Gatta A
Hepatology; 1999 Jun; 29(6):1690-7. PubMed ID: 10347109
[TBL] [Abstract][Full Text] [Related]
5. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial.
Mitzner SR; Stange J; Klammt S; Risler T; Erley CM; Bader BD; Berger ED; Lauchart W; Peszynski P; Freytag J; Hickstein H; Loock J; Löhr JM; Liebe S; Emmrich J; Korten G; Schmidt R
Liver Transpl; 2000 May; 6(3):277-86. PubMed ID: 10827226
[TBL] [Abstract][Full Text] [Related]
6. Hepatorenal syndrome.
Biswas KD; Jain AK
Trop Gastroenterol; 2002; 23(3):113-6. PubMed ID: 12693150
[TBL] [Abstract][Full Text] [Related]
7. [Hepatorenal syndrome].
Mijac D; Kezić A; Stojimirović B
Srp Arh Celok Lek; 2007; 135(1-2):98-104. PubMed ID: 17503577
[TBL] [Abstract][Full Text] [Related]
8. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure.
Laleman W; Wilmer A; Evenepoel P; Elst IV; Zeegers M; Zaman Z; Verslype C; Fevery J; Nevens F
Crit Care; 2006; 10(4):R108. PubMed ID: 16859530
[TBL] [Abstract][Full Text] [Related]
9. Hepatorenal syndrome.
Bataller R; Arroyo V; Ginès P; Sort P
Forum (Genova); 1998; 8(1):62-81. PubMed ID: 9565447
[TBL] [Abstract][Full Text] [Related]
10. Molecular adsorbent recirculating system (Mars) in patients with primary nonfunction and other causes of graft dysfunction after liver transplantation in the era of extended criteria donor organs.
Gaspari R; Cavaliere F; Sollazzi L; Perilli V; Melchionda I; Agnes S; Gasbarrini A; Avolio AW
Transplant Proc; 2009; 41(1):253-8. PubMed ID: 19249528
[TBL] [Abstract][Full Text] [Related]
11. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
[TBL] [Abstract][Full Text] [Related]
12. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response.
Sharma P; Kumar A; Shrama BC; Sarin SK
Am J Gastroenterol; 2008 Jul; 103(7):1689-97. PubMed ID: 18557715
[TBL] [Abstract][Full Text] [Related]
13. Pathogenetic factors and clinical elements in ascites and hepatorenal syndrome during liver cirrhosis.
Gentilini P; Laffi G; La Villa G; Raggi VC
Ann Ital Med Int; 1999; 14(4):264-84. PubMed ID: 10638019
[TBL] [Abstract][Full Text] [Related]
14. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion.
Guevara M; Ginès P; Fernández-Esparrach G; Sort P; Salmerón JM; Jiménez W; Arroyo V; Rodés J
Hepatology; 1998 Jan; 27(1):35-41. PubMed ID: 9425914
[TBL] [Abstract][Full Text] [Related]
15. [Efficiency of dialysis with albumin in the treatment of patients with advanced hepatic insufficiency: initial experience with the MARS system in Spain].
Avilés J; Macía M; Morales S; Pérez F; Moreno A; Navarro J; Navazo L; García J
Nefrologia; 2001; 21(4):376-85. PubMed ID: 11816514
[TBL] [Abstract][Full Text] [Related]
16. Terlipressin therapy for renal failure in cirrhosis.
Triantos CK; Samonakis D; Thalheimer U; Cholongitas E; Senzolo M; Marelli L; Leandro G; Patch D; Burroughs AK
Eur J Gastroenterol Hepatol; 2010 Apr; 22(4):481-6. PubMed ID: 19952764
[TBL] [Abstract][Full Text] [Related]
17. Hepatorenal syndrome.
Gattoni A; Marotta F; Vangieri B; Pisani G; Cristiano F
Clin Ter; 2004 Sep; 155(9):375-89. PubMed ID: 15700631
[TBL] [Abstract][Full Text] [Related]
18. New treatments of hepatorenal syndrome.
Arroyo V; Terra C; Ginès P
Semin Liver Dis; 2006 Aug; 26(3):254-64. PubMed ID: 16850375
[TBL] [Abstract][Full Text] [Related]
19. Terlipressin in hepatorenal syndrome: Evidence for present indications.
Rajekar H; Chawla Y
J Gastroenterol Hepatol; 2011 Jan; 26 Suppl 1():109-14. PubMed ID: 21199521
[TBL] [Abstract][Full Text] [Related]
20. Preconditioning by extracorporeal liver support (MARS) of patients with cirrhosis and severe liver failure evaluated for living donor liver transplantation -- a pilot study.
Choi JY; Bae SH; Yoon SK; Cho SH; Yang JM; Han JY; Ahn BM; Chung KW; Sun HS; Kim DG
Liver Int; 2005 Aug; 25(4):740-5. PubMed ID: 15998424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
